Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Publication of AR054086A1publicationCriticalpatent/AR054086A1/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Procesos para la produccion de tales formas cristalinas, composiciones farmacéuticas que comprenden tales formas cristalinas. Reivindicacion 1: La forma N-3 de 1-(3-clorofenil)-7-oxo-6-[4-(2-oxo-1(2H)piridinil)fenil]-4,5,6,7-tetrahidro-1H- pirazolo[3,4-c]-piridina-3-carboxamida cristalina, caracterizada por un SSNMR substancialmente de acuerdo con aquel mostrado en la figura 1.
ARP050104087A2004-09-282005-09-28Formas cristalinas de un compuesto de pirazolpiridina inhibidor de factor xa
AR054086A1
(es)
3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme
3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament